Chief Executive Officer
Jason is the President and Chief Executive Officer of Teligent, Inc., where he is leading our transformation into an R&D-centered pharmaceutical company.
Prior to joining Teligent in July 2012, Jason spent over eight years at Hikma Pharmaceuticals, PLC and its subsidiaries, including West-Ward Pharmaceuticals in the United States. He served in a number of roles, most recently as SVP of Sales and Marketing, where he led the acquisition of the Baxter sterile injectable facility for West-Ward. Before joining Hikma, Jason worked throughout Central and Eastern Europe as a partner at Trigon Capital, a boutique investment bank, focused on mergers and acquisitions. During his time in that region, Jason served as Chairman of the Board of Sanitas Pharmaceuticals, as well as other board positions.
Jason holds an MA (Hons) in Economics from the University of St Andrews in Scotland and an MBA from INSEAD.
General Manager & Vice President of Operations
Antonio Di Nicola joined Teligent Inc. as the General Manager and Vice President of Operations at Teligent, Buena sterile manufacturing facility in May 2019. He has over 30 years of experience in managing and directing functional teams engaged in the aseptic manufacturing process of parenterals, ointments, nasal spray, and ophthalmic products. His successes include managing and implementing several initiatives to increase efficiencies and plant productivity.
Before joining Teligent, Antonio has held positions of increased responsibility, which include Plant Manager at Renaissance, LLC, Director of Operations at DPT Labs, Director of Operations at West-Ward Pharmaceuticals, Associate Director of Manufacturing at Baxter Healthcare, and Manager of Product Compliance at Wyeth-Ayerst.
Antonio holds a BS in Nautical and Maritime Science from the Italian Naval Academy.
Chief Financial Officer
Damian joined Teligent, Inc. as the Chief Financial Officer in February 2018, after previously serving briefly on our Board of Directors in 2014. He leads the Finance, IT and Investor Relations teams.
Damian has over 25 years of Finance experience, most of which was spent in the pharmaceutical industry. He began his career in public accounting at KPMG LLP. Then, after spending nearly 14 years in a variety of roles at AstraZeneca, he served as VP Finance of Daiichi Sankyo Pharma Development, CFO of West-Ward Pharmaceuticals, SVP Finance of Heritage Pharmaceuticals and, most recently, as the CFO of Virtus Pharmaceuticals.
Damian has an undergraduate degree in Accounting from Penn State and an MBA from the University of Delaware.
Vice President, Sales and Marketing
General Manager, Canada
Mark joined Teligent in 2018 as our General Manager of Canada. He is responsible for customer engagement, product development, quality assurance, regulatory affairs, and building our vision for Teligent Canada. In addition, he actively liaisons with our supplier partners and European colleagues to drive integration across our business units.
Mark has gained experience from multiple industries, such as working with Coca Cola, Campbell’s Soup, Roche Diagnostics, Mylan Pharmaceuticals, and, most recently, as Vice President, Sales and Marketing at Mint Pharmaceuticals.
Mark is a graduate of the British Columbia Institute of Technology with a certificate in Marketing Management.
Vice President, Business Development
Eric joined Teligent in June 2016 as the Vice President of Business Development, where he leads the identification and development of new business opportunities, including acquisitions, licensing agreements, strategic alliances and new ventures.
Prior to joining Teligent, Eric served as Director of Global Business Development at Akorn, Inc. where he executed the Company’s business development strategy in generic and branded prescription pharmaceuticals, as well as in animal and consumer health products. Prior to Akorn, Eric held various roles at Baxter International Inc. in business development, strategy and commercial analytics. His background also includes over 10 years of healthcare investment management experience, including at Citadel LLC.
He holds an MS in Biotechnology from Northwestern University and a Bachelor’s degree in Chemistry and Anthropology from California State University, Fresno.
Chief Scientific Officer
Steve joined Teligent in October 2015 as our Chief Scientific Officer. In this role, he has primary responsibility for creating and executing the R&D strategy for the Company. Steve has almost 30 years of experience successfully leading the scientific functions of a number of companies in the generic and specialty pharmaceutical industry.
Prior to joining Teligent, Steve was Principal Consultant with Lachman Consultants, Inc., providing a wide array of scientific and business guidance to both pharmaceutical industry and financial investment clients. Prior to joining Lachman, Steve was with JHP Pharmaceuticals (now Endo International), Stiefel Laboratories (now GSK), Mayne Pharma (now Hospira) and Faulding Pharmaceutical.
Steve holds a BSc in Chemistry/Microbiology from the University of South Australia and an MBA from the University of Adelaide.
General Manager, Estonia
Anneli joined Teligent in February 2016 as the General Manager of Estonia. She is responsible for the company’s startup in Estonia, which will include supply chain and quality operations support to the company’s suppliers and manufacturing partners around the world.
Prior to joining Teligent, Anneli managed the Transaction Services team at KPMG Estonia. She has more than 15 years of experience in management consulting, financial advisory, investor relations and M&A. Anneli has worked at Deloitte, the Estonian Energy Company and Trigon Capital, among other firms.
She graduated from Concordia International University with a BA in international business.
Martin was appointed General Counsel in April of 2017. He has 15 years of legal experience in the pharmaceutical industry, including extensive experience in M&A, corporate, securities, finance, commercial and employment law.
Prior to joining Teligent, Martin served as Vice President and Assistant General Counsel for Endo Pharmaceuticals’ generic arm, Par Pharmaceutical, Inc., a position he held for 18 months following the acquisition of Par by Endo. Martin was with Par for over 11 years prior to the acquisition by Endo and served in a number of roles, most recently as Par’s Chief Compliance Officer.
Martin has a B.S. from Saint Joseph’s University in Philadelphia, PA, and obtained a J.D. from Villanova University School of Law in 2002.